The Effect of Intravenous Tranexamic Acid on Postoperative Ecchymoses After Upper Blepharoplasty

Understanding Postoperative Bruising in Upper Blepharoplasty

Upper blepharoplasty is one of the most commonly performed aesthetic and functional procedures in oculoplastic and plastic surgery. While the procedure itself carries a high satisfaction rate, postoperative ecchymoses (bruising) remains one of the most common concerns for patients, often influencing their decision to proceed with surgery and directly impacting their social downtime.

Periorbital bruising typically peaks at 48–72 hours and can persist for 7–14 days, causing significant aesthetic concern and psychological distress during the recovery period. Reducing this bruising has been a long-standing goal in refining the blepharoplasty experience.

What Is Tranexamic Acid (TXA)?

Tranexamic acid is a synthetic lysine analogue that inhibits fibrinolysis by blocking the lysine-binding sites on plasminogen. This prevents the breakdown of fibrin clots, effectively reducing bleeding and subsequent tissue discoloration. TXA has been widely used in orthopaedic surgery, cardiac surgery, and trauma medicine for decades.

Its application in plastic surgery — particularly in facial procedures — has gained increasing attention as surgeons seek evidence-based strategies to minimise postoperative morbidity without compromising surgical outcomes.

Mechanism of Action in Periorbital Surgery

The periorbital region is highly vascular with thin, delicate skin that makes even minimal bleeding visible as ecchymosis. When administered intravenously prior to or during upper blepharoplasty, TXA works through several mechanisms:

• Fibrinolysis inhibition: Stabilises clot formation at the surgical site, preventing secondary bleeding
• Reduced capillary oozing: Minimises the diffuse microvascular bleeding that contributes to widespread bruising
• Anti-inflammatory properties: Emerging evidence suggests TXA may modulate the inflammatory cascade, reducing tissue oedema

Clinical Evidence and Research Findings

Multiple randomised controlled trials and prospective studies have investigated the effect of IV tranexamic acid on blepharoplasty outcomes. Key findings include:

• Significant reduction in ecchymosis severity — Studies using standardised bruising scales demonstrate a 40–60% reduction in visible bruising at postoperative days 3 and 7 compared to placebo groups
• Earlier return to social activities — Patients receiving TXA reported feeling comfortable appearing in public 2–3 days sooner than control groups
• No increase in thromboembolic events — At standard doses (10–15 mg/kg IV), TXA has demonstrated an excellent safety profile in healthy surgical candidates
• Reduced periorbital oedema — A secondary benefit observed in several studies, with measurable decreases in swelling volume

Protocol at Dr. Karaaltin's Clinic

At our clinic, we employ a carefully calibrated protocol for IV tranexamic acid administration in upper blepharoplasty cases:

• Dosage: 1 g IV administered 15–20 minutes before the first incision
• Patient selection: Thorough preoperative screening excludes patients with a history of thromboembolic disease, renal impairment, or contraindications to antifibrinolytic therapy
• Combination approach: TXA is used alongside meticulous surgical technique, including precise cautery, cold compresses, and head elevation postoperatively
• Outcome tracking: Standardised photography at days 1, 3, 7, and 14 documents the recovery trajectory

Patient Benefits and Recovery Impact

The integration of IV tranexamic acid into our blepharoplasty protocol has yielded measurable improvements in the patient experience:

• Faster aesthetic recovery: Most patients show minimal visible bruising by day 5–7 rather than the traditional 10–14 days
• Improved satisfaction scores: Patients report higher confidence during the early postoperative period
• Reduced analgesic requirements: Less tissue trauma and oedema correlates with decreased postoperative discomfort
• Professional downtime reduction: Many patients return to work or social engagements within 5–7 days

Safety Considerations

While TXA is generally well-tolerated, responsible use requires careful patient evaluation. Absolute contraindications include active thromboembolic disease, subarachnoid haemorrhage, and severe renal impairment. Relative contraindications include a personal or family history of deep vein thrombosis or pulmonary embolism.

At the doses used in blepharoplasty (significantly lower than those in major surgery), the risk–benefit ratio strongly favours administration in appropriately selected patients.

Conclusion

Intravenous tranexamic acid represents a simple, safe, and evidence-based adjunct that meaningfully reduces postoperative ecchymoses after upper blepharoplasty. By incorporating TXA into a comprehensive perioperative protocol, we can offer patients a smoother recovery, reduced social downtime, and enhanced overall satisfaction with their surgical experience.

For patients considering upper blepharoplasty, this pharmacological advancement is one of many ways Prof. Dr. Karaaltin's clinic prioritises both surgical precision and patient comfort throughout the entire treatment journey.